The effect of Pb2+ on the structure and hydroxyapatite binding properties of osteocalcin  by Dowd, T.L. et al.
The e¡ect of Pb2 on the structure and hydroxyapatite binding properties
of osteocalcin
T.L. Dowd a;*, J.F. Rosen a, L. Mints b, C.M. Gundberg c
a Department of Pediatrics, Monte¢ore Medical Center, Albert Einstein College of Medicine, Moses Bldg. Room 401, 111 East 210th Street,
Bronx, NY 10467, USA
b Department of Biochemistry and the Laboratory for Macromolecular Analysis and Proteomics, Albert Einstein College of Medicine,
Bronx, NY, USA
c Department of Orthopedics, Yale University School of Medicine, New Haven, CT, USA
Received 14 June 2000; received in revised form 2 October 2000; accepted 12 October 2000
Abstract
Lead toxicity is a major environmental health problem in the United States. Bone is the major reservoir for body lead.
Although lead has been shown to impair bone metabolism in animals and at the cellular level, the effect of Pb2 at the
molecular level is largely unknown. We have used circular dichroism (CD), and a hydroxyapatite binding assay to investigate
the effect of Pb2 on the structure and mineral binding properties of osteocalcin, a noncollagenous bone protein. The CD
data indicate Pb2 induces a similar structure in osteocalcin as Ca2 but at 2 orders of magnitude lower concentration. These
results were explained by the more than 4 orders of magnitude tighter binding of Pb2 to osteocalcin (Kd = 0.085 WM) than
Ca2 (Kd = 1.25 mM). The hydroxyapatite binding assays show that Pb2 causes an increased adsorption to hydroxyapatite,
similar to Ca2, but at 2^3 orders of magnitude lower concentration. Low Pb2 levels (1 WM) in addition to physiological
Ca2 levels (1 mM) caused a significant (40%) increase in the amount of mineral bound osteocalcin as compared to 1 mM
Ca2 alone. These results suggest a molecular mechanism of Pb2 toxicity where low Pb2 levels can inappropriately perturb
Ca2 regulated processes. In-vivo, the increased mineral bound osteocalcin could play a role in the observed low bone
formation rates and decreased bone density observed in Pb2-intoxicated animals. ß 2001 Elsevier Science B.V. All rights
reserved.
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1. Introduction
Lead toxicity is a major public health problem in
the United States. Despite governmental regulations,
elevated blood lead levels (v 0.5 WM) have been re-
cently reported to be highest among very young
children (aged 1^5 years) as well as older adults
v 50 years old [1].
Bone is the major reservoir of body lead account-
ing for 75% of total body lead in normal children
and over 90% in adults [2,3]. Bone lead values have
been found to be elevated in lead-intoxicated chil-
dren [4] and in adults who have either been occupa-
tionally exposed or have had past exposure to higher
environmental levels [5,6]. Bone is known to be an
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important endogenous source capable of releasing
stored lead to other soft tissues and organs in normal
and pathological states.
Lead has been found to have detrimental e¡ects on
bone. Chronic low level lead exposure has been as-
sociated with decreased stature and chest circumfer-
ence in children less than 7 years of age [7,8]. Several
studies have indicated that lead can e¡ect both bone
formation and resorption [9^11] resulting in reduced
bone density in experimental animals [12]. At the
cellular level, lead has been shown to perturb calcium
homeostasis and alter cellular metabolism or activity
of osteoclasts [13] and osteoblasts [14^19]. Little is
known about the e¡ect of lead at the protein level.
The comparison of the e¡ect of a toxic metal ion,
Pb2, with an essential metal ion, Ca2, on the struc-
ture and activity of a bone matrix protein from a
target tissue and from a site of concentrated storage
has not been reported.
Osteocalcin (49 amino acids) is an abundant non-
collagenous matrix protein found in bone [20,21] and
dentin [22]. It is synthesized exclusively by osteo-
blasts [23,24] and odontoblasts [25]. Osteocalcin is
deposited in the mineralized matrix, but a small
amount is detected in serum where it circulates at
levels that re£ect the metabolic state of bone in nor-
mal and pathologic conditions [26]. Osteocalcin con-
tains three Q-carboxyglutamic acid residues (Gla)
which can bind Ca2 in solution and in the mineral
phase [27]. Several early in vitro studies have sug-
gested a role for osteocalcin in bone resorption
[28,29], osteoclast di¡erentiation [29^31] or crystal
formation and growth [32^34]. However, recent stud-
ies indicate that osteocalcin may play a regulatory
role in bone formation and remodeling. In geneti-
cally engineered osteocalcin-depleted (knockout)
mice, there was increased bone mass and conse-
quently increased biomechanical strength while
bone formation rates were increased [35]. Subsequent
studies indicated an immature mineral phase in these
animals [36].
We have previously shown that low levels of Pb2
can displace Ca2 from osteocalcin and lead was
shown to have a much higher a⁄nity for osteocalcin
than that of Ca2 [37] at very low ionic strength.
Circular dichroism studies have shown Ca2 induces
an K-helical conformation in osteocalcin which cor-
relates with maximum adsorption of osteocalcin to
hydroxyapatite [38]. Another essential metal, Mg2,
was also found to induce an K-helical conformation
yet inhibit the binding of osteocalcin to hydroxyap-
atite [39]. The e¡ect of a toxic metal, Pb2, on the
secondary structure and hydroxyapatite binding
properties of osteocalcin have not been determined.
Lead may exert its toxic e¡ect by altering the second-
ary structure of osteocalcin and decreasing its ad-
sorption to hydroxyapatite. Alternatively, Pb2 may
induce a similar secondary structure in the protein as
Ca2 and induce an inappropriate increase in hy-
droxyapatite binding at much lower concentrations.
The purpose of this paper is to investigate the
e¡ect of Pb2 on the structure and functional proper-
ties of osteocalcin using circular dichroism spectros-
copy and hydroxyapatite binding assays. Similar
data were collected for the essential metal, Ca2,
and apo-osteocalcin for comparative purposes.
2. Experimental procedures
2.1. Preparation of osteocalcin
Bovine osteocalcin was prepared from calf bone by
a previously described method [40]. The purity of the
protein was determined by polyacrylamide gel elec-
trophoresis, reverse-phase high-performance liquid
chromatography (HPLC) and N-terminal amino
acid analysis. This protein was used for the CD stud-
ies and hydroxyapatite binding assays.
Some of the protein in this study was also synthe-
sized using solid phase peptide synthesis methodol-
ogy on an ABI 433 peptide synthesizer using Fmoc
protocols [41]. Reagents (piperidine, HOBT/HBTU
activation kit, diisopropylethylamine, NMP, DCM
and Fmoc standard amino acids) were purchased
from ABI. Fmoc Q-carboxyGlu(OtBu)2-OH (Gla)
was purchased from Bachem. Fmoc preloaded amino
acid Wang resin was purchased from Advanced
Chem Tech.
Peptide resins were cleaved/deprotected by a mix-
ture of TFA/thioanisole/EDT/phenol/H2O for 2.5 h,
precipitated by tert-butyl methyl ether and then
washed. The disul¢de bond between the two Cys
residues was formed by slow air oxidation methods
[42] and the protein was puri¢ed by reverse-phase
HPLC. Synthetic bovine osteocalcin was character-
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ized by analytical HPLC, electrospray mass spec-
trometry and amino acid analysis.
The synthetic protein was found to give similar
CD and one-dimensional (1D) NMR spectra and
to bind to hydroxyapatite in a similar manner as
the osteocalcin prepared from calf bone. The syn-
thetic protein was used for some of the CD experi-
ments in this paper.
To ensure that there was no residual metal binding
to osteocalcin resulting from the various preparation
procedures, low concentrations of osteocalcin (V200
WM) were treated with 2 mM EGTA. The protein
was then concentrated in a Centricon 3 concentrator
and subsequently washed ¢ve times (1/10 dilution)
with distilled deionized H2O to decrease the concen-
tration of EGTA. The ¢nal protein concentrate con-
tained negligible levels of EGTA which were then
further diluted by a factor of 1000 for protein con-
centrations needed in this study.
2.2. Circular dichroism experiments
Bovine osteocalcin solutions were prepared at pro-
tein concentrations at or near 50 WM and dissolved
in 150 mM NaCl and 20 mM Tris at a pH of 7.4.
Protein concentrations were measured spectrophoto-
metrically using the absorbance coe⁄cient
A1%1cm = 13.3 at 280 nm.
CD spectra were collected at various concentra-
tions of Ca2 and Pb2 (see Section 3) at 37‡C.
All CD spectra were collected on a Jasco J-720
spectropolarimeter using a 0.05 cm pathlength
water-jacketed cuvette regulated for temperature
control at 37‡C. Spectra were typically measured at
200^250 nm, using a bandwidth of 1.0 nm, a resolu-
tion of 0.5 nm and spectra were the result of the
average of three accumulations. Each spectrum was
corrected for solvent e¡ects. Secondary structure es-
timates were calculated from the CD spectra using
the Yang method of analysis [43].
2.3. Determination of the Kd for Pb2
+-osteocalcin
For the determination of the Kd for Pb-osteocal-
cin, a 0.25^0.5 WM protein solution (dissolved in the
bu¡er described above) was titrated with lead nitrate
and CD spectra were collected at 37‡C in a 5 cm
pathlength water-jacketed cuvette. The total Pb2
concentrations added to all solutions were deter-
mined by graphite atomic absorption spectroscopy
using a modi¢cation of a previously published meth-
od [44]. The molecular ellipiticity at 222 nm was
recorded for the metal-free protein (apoprotein) as
well as at each addition of Pb2. The change in the
molar ellipticity at 222 nm from that of the apo-
protein (va) was calculated for each addition of
Pb2 and plotted as function of total Pb2 added.
The data were ¢t to the following equation [45]:
v a  v amaxPb2=Kd  Pb2 1
where va is the change in the molar ellipticity at 222
nm between the protein with added Pb2 and that of
the apo-protein, [Pb2] is the free Pb2 concentra-
tion, vamax is the maximum change in va and Kd is
the dissociation constant for the Pb2^osteocalcin
complex. The value for free Pb2, [Pb2], at each
addition of total Pb, [PbT], was calculated from the
di¡erence between the measured [PbT] and the con-
centration of Pb bound, [PbB], calculated from the
following equation [37]:
PbB  Kd  OstT  PbT3Kd  OstT
PbT234OstTPbT1=2=2 2
where [PbT], as measured from atomic absorption
and the protein concentration [OstT], were used to
extract the parameters Kd and vamax using Eqs. 1
and 2. The best values of Kd and vamax, giving the
smallest di¡erence between the observed and calcu-
lated va, were obtained iteratively minimizing the
error square sum to obtain the best ¢t.
2.4. Hydroxyapatite binding assays
A stock solution of hydroxyapatite (Ca/P molar
ratio of 1.67 þ 0.02 and surface area of 59.56 m2/g
by N2 adsorption) (5 mg/ml) was dissolved in 150
mM NaCl, 20 mM Tris (pH 7.4), and serially diluted
to make hydroxyapatite solutions with ¢nal concen-
trations of 1.66, 0.833, 0.416, 0.21, 0.104, and 0.052
mg/ml. Hydroxyapatite in the serially diluted samples
was quantitated by dissolving the crystal in 0.5 N
HCl and quantitating total calcium with £ame
atomic adsorption spectroscopy. The quantitated hy-
droxyapatite correlated very closely (r = 0.994) with
hydroxyapatite concentrations calculated by serial
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dilution. Unlabeled bovine osteocalcin (V25 Wg/ml),
in 150 mM NaCl, 20 mM Tris (pH 7.4) with Ca2
concentrations of 0, 1 or 6 mM or Pb2 concentra-
tions of 1 or 10 WM were added to the various hy-
droxyapatite suspensions and shaken vigorously for
1 h. The extent of crystal dissolution after vortex
shaking was assessed by measuring total Ca2 in
the supernatant of the 1.66 mg/ml hydroxyapatite
sample using £ame atomic absorption spectroscopy.
It was found that crystal dissolution was only 0.7%
in these experiments and not a¡ected by the presence
of any metal ion. Nonspeci¢c binding of osteocalcin
was assessed for each concentration of metal ion.
The suspensions were then centrifuged for 10 min
at 10 000Ug and an aliquot of the supernatant was
quantitated by radioimmunoassay as previously de-
scribed [40]. The total protein concentration avail-
able for binding to hydroxyapatite (1.4^2.4 WM),
and the concentration of free, unbound osteocalcin
in the supernatant from the various metal ion and
hydroxyapatite containing solutions were deter-
mined. Brie£y, the data was analyzed according to
previously published methods and ¢t to a Langmuir
isotherm model adapted to analyze the adsorption of
proteins to apatite surfaces [39]:
C=Q  C=N  1=NK
where C is the solution concentration of free osteo-
calcin in equilibrium with hydroxyapatite, Q is the
amount of osteocalcin adsorbed per unit of hydroxy-
apatite surface (using the hydroxyapatite-speci¢c sur-
face area of 59.56 m2/g), N (nmol/m2) is the maxi-
mum number of adsorption sites per square meter of
hydroxyapatite and K (ml/nmol) is the a⁄nity of
osteocalcin for the adsorption sites. Three or four
experiments were conducted on each Ca2 (0,1 and
6 mM), Pb2 (10 WM) and Ca2 (1 mM) plus Pb2 (1
WM) containing solution and all were performed in
duplicate or triplicate. Plots of C/Q vs. C were con-
structed for all free protein concentrations in a par-
ticular solution (30^50 points) and linear regression
was performed on all the data points. The 95% con-
¢dence limits were also calculated for the slope and
intercept using these plots. In addition, the area of a
single binding site, (1/NM), was calculated for osteo-
calcin in each metal containing solution where the
value of N is de¢ned above and M is Avogadro’s
number.
3. Results
3.1. Circular dichroism studies
In order to assess and compare the e¡ect of Pb2
and Ca2 on the gross features of the structure of
osteocalcin, circular dichroic spectra were collected
at various total Pb2 and Ca2 concentrations. Fig.
1A shows CD spectra at Ca2 concentrations rang-
ing from 0.1^6 mM. The CD spectrum of the apo-
protein exhibits a negative band around 204 nm con-
sistent with a random coil structure and very little
signal at 222 nm. This is consistent with an K-helical
content of 9 5%. A shift in the negative band to 208
nm, as well as an increasingly negative band ob-
served at 222 nm, was observed with Ca2 addition.
This indicated that Ca2 addition induces an K-hel-
ical conformation in the protein with the maximal
conformational change occurring at 5^6 mM Ca2.
Results from three di¡erent experiments were consis-
tent with a Ca2-induced average K-helical content of
18%.
Fig. 1B shows a CD titration with Pb2. As with
Ca2, increasing Pb2 concentration induced a shift
in the negative band from 202 (random coil) to 208
nm and the observation of a negative band at 222
nm. The average result from three di¡erent experi-
ments indicated a Pb2-induced conformational
change of 20% K-helix. In contrast to Ca2, the max-
imal conformational change occurred at Pb2 con-
centrations which are 2 orders of magnitude lower
than those required for a Ca2-induced conforma-
tional change (55 WM). The protein concentration
in these experiments was 50 WM and the maximum
change occurred at 55 WM Pb2, indicating very tight
binding of Pb2 to osteocalcin. The CD spectra in
the presence of Ca2 and Pb2 were collected in the
concentration range of 0.029^0.29 mg/ml osteocalcin
with similar conformational changes observed at all
protein concentrations. This suggests that the CD
spectrum in this wavelength region is associated
with a change in the backbone conformation of os-
teocalcin rather than due to protein-protein interac-
tions.
3.2. Kd determination
We had previously reported that Pb2 had a much
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lower Kd (higher a⁄nity) for osteocalcin as com-
pared to Ca2 at low ionic strength ([NaCl] = 0)
[37]. To ensure that this di¡erence in a⁄nity was
maintained at physiological ionic strength (150 mM
NaCl) Kd measurements were determined from CD
titration data. The calculations are described in the
experimental section. Fig. 2A and B show the change
in molar ellipticity relative to the metal-free protein
(apoprotein) as a function of total Pb2 and Ca2,
respectively. These data could be ¢t to a model of
chemical equilibria with one binding site using Eqs. 1
and 2:
M2 OstHM23Ost
The best ¢t yielded a Kd for Pb2-osteocalcin of
85 þ 12 nM and a Kd for Ca2-osteocalcin of
1.25 þ 0.19 mM. These data show that Pb2 binds
Fig. 2. (A) The change in molar ellipiticity (v3) at 222 nm,
with respect to the apo-protein, for osteocalcin with added
Ca2. The data could be ¢t to a one-binding-site model with a
Kd of 1.25 þ 0.19 mM. (B) The change in molar ellipiticity (v3)
at 222 nm, with respect to the apo-protein, for osteocalcin with
added Pb2. The data could be ¢t to a one-binding-site model
with a Kd of 0.085 þ 0.012 WM.
Fig. 1. (A) The e¡ect of Ca2 on the CD spectrum of osteocal-
cin, showing the CD spectrum for apo-osteocalcin (solid line,
signal at 204 nm) and the e¡ect of increasing amounts of Ca2
(0.1, 0.5, 0.7, 1.0, 3.0, 5.0 mM, dotted lines) and 6.0 mM Ca2
(solid line, signal at 208 and 222 nm) on the spectrum. An in-
creasing shift of the signal from 204 nm for apo-osteocalcin
(random coil) to 208 and 222 nm (K-helical conformation) with
increasing Ca2 is observed. (B) The e¡ect of Pb2 on the CD
spectrum of osteocalcin, showing the CD spectrum for apo-os-
teocalcin (solid line, signal at 204 nm) and the e¡ect of increas-
ing amounts of Pb2 (10, 25, 31, 40, 48 WM, dotted lines) and
55 WM Pb2 (solid line, signal at 208 and 222 nm) on the spec-
trum. An increasing shift of the signal from 204 nm for apo-os-
teocalcin (random coil) to 208 and 222 nm (K-helical conforma-
tion) with increasing Pb2 is observed.
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to osteocalcin with an a⁄nity which is over 4 orders
of magnitude tighter than that of Ca2 at physiolog-
ical ionic strength. The data in this experiment could
be ¢t to one binding site but does not rule out the
existence of weaker binding sites. The purpose of the
measurement was to explain the di¡erence in concen-
tration of the two ions required to induce the con-
formational changes. Weaker binding sites probably
do not contribute to the observed conformational
changes.
3.3. Hydroxyapatite binding assays
A comparison between the e¡ect of Ca2 and Pb2
on the function of osteocalcin was assessed using
hydroxyapatite binding assays. The data was ana-
lyzed as described in Section 2. The values for K
and N for the apo-protein and at each Ca2 and
Pb2 solution are reported in Table 1. For each so-
lution, all data points (30^50) were used to calculate
the best ¢t line as well as the 95% con¢dence limits
on the line (errors in Table 1). For presentation pur-
poses, the average values of C and C/Q (5^20 points)
were calculated at each hydroxyapatite concentration
and are shown in Fig. 3A^C for the di¡erent solution
conditions.
Fig. 3A shows the concentration dependent e¡ect
of Ca2 on the binding of osteocalcin to hydroxyap-
atite and Table 1 gives the binding parameters. Fig.
3A indicates an increase in the occupancy of the sites
on the crystal with increasing total [Ca]T concentra-
tions. There was a signi¢cant di¡erence (p9 0.05)
between the slopes of apo-osteocalcin (metal-free)
and that induced by 1 mM [Ca]T, indicating an in-
crease of 30% in the occupancy of the sites on the
crystal at physiological [Ca2]f . The slope with 1 mM
[Ca]T was signi¢cantly (p9 0.05) higher than that
with 6 mM [Ca]T, indicating an increase of 25% in
the occupancy of sites on the hydroxyapatite crystal
with an increase in Ca2 above the physiological lev-
el. The slope for the apo-protein (metal-free) was
also signi¢cantly larger (p9 0.05) than that induced
by 6 mM [CaT]. This indicated that addition of 6 mM
[Ca]T results in a 62% increase in the number of
adsorption sites on the hydroxyapatite crystal as
compared to the metal-free apo-protein. These re-
sults can be explained by the fact that a greater frac-
tion of the protein is complexed to Ca2 at higher
Ca2 concentrations (44% at 1 mM and 83% at
6 mM). It was also observed that the maximum
area of a single binding site decreased in the presence
of Ca2. This is probably due to the Ca2-induced
conformational change in the protein. Although the
average values for the a⁄nities (K) of osteocalcin for
the sites on the crystal were larger in the presence of
Ca2, they are not signi¢cantly di¡erent from the
a⁄nity for the metal-free apo-protein.
Fig. 3B shows a comparison between the metal-
free apo-protein and the e¡ect of saturating levels
of Pb2 (10 WM) on osteocalcin binding to hydroxy-
apatite. This ¢gure shows that Pb2 induced a sim-
ilar e¡ect on the binding of osteocalcin to hydroxy-
apatite as Ca2. However, due to the much higher
a⁄nity of Pb2 for osteocalcin as compared to Ca2,
a much lower metal ion concentration was necessary
to induce the same amount of binding to hydroxy-
apatite. The di¡erence in slopes between Ca2- and
Pb2-treated osteocalcin and the apo-protein are
clearly visible. The Pb2 result is also due to the
fact that at 10 WM Pb2 most of the protein is com-
plexed to Pb2 (V95%) and in a conformationally
altered state. There was a signi¢cant di¡erence
(p9 0.05) in the slopes between the metal-free apo-
protein and that of 10 WM Pb2 which indicated an
Table 1
Binding parameters for Apo-, Ca2- and Pb2-osteocalcin
Apo-osteocalcin 1 mM CaT 6 mM CaT 10 WM PbT 1 mM Ca2+1 WM PbaT
No. of binding sites (nmol/m2) 77 þ 7 100 þ 9b 125 þ 13b;c 143 þ 22b;c 140 þ 22b;c
Binding constant, K (ml/nmol) 9.2 þ 4 12.5 þ 6 11.4 þ 5 7.0 þ 4 13 þ 5
Area of a single binding site (Aî 2) 2076 1350 1195
aTotal protein concentration was 1.4^1.79 WM.
bSigni¢cantly di¡erent (p9 0.05) from apo-osteocalcin.
cSigni¢cantly di¡erent (p9 0.05) from 1 mM Ca2.
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increase of 85% in the occupancy of sites on the
crystal with 10 WM Pb2. No signi¢cant di¡erence
was observed between the a⁄nity constants with
Pb2 as compared to the metal-free apo-protein or
Ca2 bound protein. As was seen with Ca2, the area
of a single binding site was also decreased, as com-
pared to the apo-protein, but with much lower levels
of Pb2. This was most likely due to the conforma-
tional change induced by Pb2 on the protein.
To investigate the e¡ect of Pb2 on the binding of
osteocalcin to hydroxyapatite under physiologically
relevant conditions the experiment was conducted
in the presence of both 1 mM Ca2 and 1 WM
Pb2. Fig. 3C shows a signi¢cant (40%) increase in
the occupancy of the protein on the crystal from
physiological Ca2 levels with the added presence
of 1 WM Pb2. This e¡ect is due to the added amount
of Pb2 producing a higher fraction of metal bound
protein than that which is produced by 1 mM Ca2
alone. Since Pb2 has a much higher a⁄nity for the
protein, all of the 1 WM Pb2 would be bound and
1 mM Ca2 would complex 44% of the remaining
protein. This would indicate that 75^85% of the pro-
tein would be in a metal complexed state at the total
protein concentrations used in this experiment. Since
Pb2 induces a similar secondary structure and hy-
droxyapatite binding as Ca2, its added presence
produces an increased e¡ect on the hydroxyapatite
binding. The number of binding sites on the crystal
in the presence of 1 mM Ca2 and 1 WM Pb2 was
not signi¢cantly di¡erent from the number of bind-
ing sites induced by 6 mM Ca2 or by 10 WM Pb2
alone.
To ensure that the protein was not denatured and
that it maintained its conformation during the mix-
ing period with hydroxyapatite, CD spectra were col-
lected after 1 h of vortex shaking on protein samples
of the apo-protein, protein in 6 mM Ca2 and 10 WM
Pb2. The CD spectra revealed that the protein con-
formation was indistinguishable from that obtained
without shaking.
Fig. 3. (A^C) Binding isotherms for apo-osteocalcin in the pres-
ence of Ca2 and Pb2. Each point represents an average (5^25
points) at a particular hydroxyapatite concentration. The e¡ect
of Ca2 (A) on the binding of osteocalcin to hydroxyapatite for
apo-osteocalcin (E), osteocalcin with 1 mM Ca2 (a), and
6 mM Ca2 (O). The e¡ect of Pb2 (B) on the binding of
osteocalcin to hydroxyapatite for apo-osteocalcin (E), osteo-
calcin with 6 mM Ca2 (O), and 10 WM Pb2 (8). The bind-
ing isotherm for apo-osteocalcin (E), 1 mM Ca2 (a) and 1 mM
Ca2 and 1 WM Pb2 (b) is shown in C.
6
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4. Discussion
Very little is known about the e¡ect of a toxic
metal on the secondary structure and functional
properties of proteins. The e¡ect of a toxic metal,
Pb2, on the secondary structure and hydroxyapatite
binding properties of osteocalcin has not been previ-
ously reported. Our results concerning the e¡ect of
Ca2 on the structure and activity of osteocalcin was
obtained for comparative purposes with a toxic met-
al. These results are in reasonable agreement with
literature values reported previously for the e¡ect
of Ca2 on osteocalcin. We found that Ca2 induces
an K-helical structure in 18% of the protein. This is
in reasonable agreement with previous studies where
values of 15^31% K-helix were observed by CD
[46,47] for bovine Ca2-osteocalcin. The Kd for
Ca2-osteocalcin measured in this study (1.25 mM)
is also in reasonable agreement with previously re-
ported Kd measurements, at physiological ionic
strength, ranging from 0.8 mM to 3 mM depending
on the species [48,49].
In this study we have shown that Pb2 induces a
similar percentage of K-helical conformation in os-
teocalcin as Ca2 but at much lower concentrations.
This can be explained by the over 4 orders of mag-
nitude tighter binding of Pb2 to osteocalcin as com-
pared to Ca2. Previous studies have shown that the
Q-carboxyglutamic acid residues (Gla) were necessary
for binding Ca2 in solution [27] and for the max-
imum K-helical conformational change detected by
CD [38,47]. Our previous data [37] together with
the CD data reported here suggest that Pb2 inter-
acts similarly with the Gla residues as Ca2. Using
43Ca NMR and monitoring the 43Ca T1 we showed
that Pb2 can displace Ca2 from osteocalcin [37].
Since Pb2 can displace Ca2 it must bind to similar
coordinating ligands. The 1H NMR spectra also
showed similar alterations in resonances where
GlaL and GlaQ protons occur with Ca2 or Pb2
addition [37]. The data suggest that Pb2 and Ca2
bind to the same site where at least some of the
coordinating ligands are the same for both metal
ions and that the Gla residues are involved in coor-
dinating both Ca2 and Pb2.
We found no signi¢cant di¡erence (within our ex-
perimental error) in the binding a⁄nities, K, of the
protein for the crystal at any of the ion concentra-
tions studied. An earlier study reported that Ca2
(5 mM) induced an K-helical conformation in osteo-
calcin and enhanced the binding of osteocalcin to
hydroxyapatite [38,39]. The previous study, using
125I-labeled chicken osteocalcin, found that the en-
hanced binding with Ca2 was due to the a⁄nity
of Ca2-osteocalcin to hydroxyapatite being greater
than that of the apo-protein and that the number of
binding sites was the same [39]. Our results for Ca2
may di¡er on the binding parameters because of the
species di¡erence and the fact that 125I-labeled pro-
tein was used for estimation of binding in the pre-
vious study rather than by direct measurement as we
have used here.
Our results on the e¡ect of Pb2 on osteocalcin
binding to hydroxyapatite have not been previously
reported. Both Ca2 and Pb2 are shown to increase
the number of sites occupied on the crystal by the
protein. Pb2 was shown to increase the number of
sites on the crystal at 2^3 orders of magnitude lower
concentration than Ca2. These results are explained
by the increased amount of protein complexed to the
metal ions and in a conformationally altered state at
higher free metal ion concentrations. The greater af-
¢nity of osteocalcin for Pb2 as compared to Ca2
explains the concentration di¡erence required for the
same amount of binding. In our study, the fact that
the binding a⁄nity for the crystal did not change
with Ca2 or Pb2 addition suggests that similar
functional groups on the amino acids and at the
adsorption sites are involved in the adsorption pro-
cess. The area of a single binding site was found to
decrease with concentrations of Ca2 and Pb2
where most of the protein is in the metal bound state
(1350, 1195 and 2076 Aî 2 for Ca2-, Pb2- and apo-
osteocalcin, respectively). This suggests that the apo-
protein may have a more elongated conformation
than that of the more structured Ca2 and Pb2 pro-
tein complexes. A 2D NMR study on rabbit Ca2-
osteocalcin detected a set of long range NOEs indi-
cating the proximity of Leu2, Leu36, Ala33 and
Phe45 as well as Val36 to Tyr42 which served to
de¢ne a hydrophobic core for the molecule [46].
We have previously shown for bovine osteocalcin
that Pb2 induces a similar 1D NMR spectrum as
Ca2 with similar alterations in hydrophobic residues
as reported in rabbit Ca2-osteocalcin [37]. The alter-
ations in the resonances of hydrophobic residues
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with Ca2 and Pb2 in bovine osteocalcin were not
observed in the 1D NMR spectrum of the metal-free
apo-protein. This suggests that a hydrophobic core
may be formed with Ca2 and Pb2 in bovine osteo-
calcin as well. The K-helical structural change ob-
served by CD and the hydrophobic interactions be-
tween nonsequential residues may produce a less
elongated structure in Ca2- and Pb2-osteocalcin,
as compared to the apo-protein, and may allow
more molecules to ¢t on the crystal. It is also possi-
ble that the metal induced structural change produ-
ces a conformation in the protein which is more
compatible with the binding sites on the crystal. A
2D NMR high resolution structure of bovine Ca2-
and Pb2-osteocalcin is currently in progress which
will be able to directly address this.
A model for Ca2-osteocalcin was proposed [38] in
which Ca2 induces an K-helical structure whereby
the spacing between the Gla residue side chains co-
incides with the spacing between the Ca2 atoms in
the hydroxyapatite crystal [50]. This allows for bind-
ing to the bone via uncoordinated Gla residues. The
conformational change observed with Ca2 and Pb2
in our study is also consistent with a structure which
is more compatible than the apo-protein with the
binding sites on the crystal. Although it has not yet
been shown, it is quite conceivable that the interac-
tion of Pb2-osteocalcin with hydroxyapatite is sim-
ilar to the proposed model for Ca2-osteocalcin. In
this study lead was shown to induce a similar struc-
ture in the protein. It has been reported that lead can
substitute for Ca2 in the hydroxyapatite crystal [51]
so that the spacing between the Pb2 atoms would be
the same as that between the Ca2 atoms. In vitro
studies have shown that Pb2 can displace Ca2 in
hydroxyapatite forming lead-apatite after periods of
5^45 days [52]. In fact, it is possible that the protein
may have a higher a⁄nity for a Pb2 substituted
crystal since we have shown this to be the case
with Pb2 in solution.
Our data shows that the binding of osteocalcin to
hydroxyapatite is a Ca2 regulated process. More
protein can bind to hydroxyapatite at concentrations
of Ca2 which are greater than 1 mM. It is possible
that during bone mineralization there are local in-
creases in Ca2 which may be a signal for a confor-
mational change and increased binding of osteocalcin
to the bone crystal. We show that 1 WM Pb2 added
to physiological Ca2 (1 mM) produces a signi¢cant
(V40%) increase in the number of sites occupied on
the crystal over that observed with 1 mM Ca2
alone. Therefore, low Pb2 levels would mimic the
signal at physiological Ca2 concentrations and pre-
maturely increase the binding of osteocalcin to the
bone crystal.
Since bone is the major reservoir for total body
Pb2 even low blood levels can cause a signi¢cant
accumulation of Pb2 in bone over time. Bone lead
is indicative of past exposure with a half-life of 16
years [53] and has been found to increase with age
[54]. In addition, several studies have provided evi-
dence that bone extracellular £uid is compartmental-
ized [55]. Depending on the level of free Pb2 near
the bone surface and/or the presence of Pb2 in bone
mineral, more osteocalcin may be bound to the bone
in Pb2 exposed individuals.
The biological relevance of out ¢ndings to the po-
tential e¡ects of lead intoxication on bone metabo-
lism is limited by the fact that the function of osteo-
calcin is not precisely known. A role for osteocalcin
in bone resorption is provided by experiments show-
ing osteocalcin is a chemoattractant for osteoclast
precursor cells [56,57] and may function as a resident
signal for the recruitment and di¡erentiation of bone
resorbing cells [29,58]. More recent studies with the
osteocalcin knockout mouse suggest a role in the
regulation of bone remodeling [35,36]. Further sup-
port for this comes from the recent demonstration of
osteocalcin receptors on osteoblasts [59]. A number
of studies have shown that lead can a¡ect bone re-
modeling in lead exposed animals as well as organ
culture [9^13]. Osteocalcin may act either in free so-
lution or bound to mineral to e¡ect the biological
response. If osteocalcin acts as a speci¢c cellular sig-
nal, alterations in secondary structure or variation in
the equilibrium between bone and blood may result
in downstream physiologic changes. Increased bind-
ing of the protein to hydroxyapatite by Wmolar
amounts of lead may alter bone remodeling. These
alterations could contribute to the decreased bone
formation rate [10], increased bone resorption [9,11]
and to reduced bone density observed in lead intoxi-
cated animals [12]. It is possible, that the alteration
of normal osteocalcin function in lead-intoxicated
individuals could exacerbate age-related or post-
menopausal bone loss. The increased rate of bone
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turnover in elderly males and females and in post-
menopausal women may provoke an increase in the
release of stored lead [60]. In fact, a recent CDC
report indicated that blood lead levels (v 0.5 WM)
are highest in children from 1^5 years old and in
individuals s 50 years old [1]. If osteocalcin is an
important modulator of bone turnover, the interac-
tion of lead with osteocalcin may promote the fur-
ther release of lead from the bone.
There are no structural and functional studies con-
cerning the e¡ect of Pb2 on Ca2 binding proteins.
The results reported in this paper show that at the
molecular level, as at the cellular level, low Pb2
levels can perturb Ca2 regulated processes. Our re-
sults on the e¡ect of Pb2 on the structure and prop-
erties of osteocalcin may be relevant to other phys-
iologically important Ca2-binding proteins. Low
lead levels may a¡ect calmodulin, which is activated
by a signal of increased free Ca2, and contribute to
neurological or other disorders observed in Pb2 tox-
icity.
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